Alumis Inc. (NASDAQ:ALMS) Receives $26.83 Average PT from Analysts

Alumis Inc. (NASDAQ:ALMS) has earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $26.83.

ALMS has been the subject of several analyst reports. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. HC Wainwright reduced their target price on shares of Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st.

Alumis Price Performance

Shares of ALMS opened at $9.00 on Friday. Alumis has a fifty-two week low of $7.66 and a fifty-two week high of $13.53. The business’s 50-day simple moving average is $10.56.

Hedge Funds Weigh In On Alumis

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new stake in shares of Alumis during the 3rd quarter worth approximately $27,000. MetLife Investment Management LLC acquired a new position in Alumis during the third quarter worth $89,000. Barclays PLC acquired a new position in Alumis during the third quarter worth $197,000. Maven Securities LTD acquired a new stake in Alumis in the second quarter valued at $332,000. Finally, Towerview LLC increased its position in shares of Alumis by 22.6% in the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after buying an additional 70,000 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.